News

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

Details

ImCheck Therapeutics announced the publication of the preclinical to clinical development of its lead immuno-oncology program, ICT01. The publication in the medical journal Science Translational Medicine details ImCheck’s butyrophilin (BTN)-based immuno-oncology approach and positions ImCheck as a pioneer in a nascent field of immunomodulation. 

iOmx Therapeutics raises EUR 65 million in Series B round

Details

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million. 

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

Details

ImCheck Therapeutics today presented data at the ESMO Congress 2021 from its ongoing EVICTION Phase I/IIa clinical trial with its lead antibody ICT01showing anti-tumor immune responses, resulting in increased tumor infiltration and disease control in patients with a variety of relapsed/refractory solid tumors. 

  1. TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System
  2. Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System
  3. CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer
  4. ONWARD Completes $32 Million Financing Round
© Wellington Partners, 2021.